Gilead Sciences (GILD) Retained Earnings (2009 - 2026)
Gilead Sciences' (GILD) quarterly Retained Earnings came in at $78.0 million in Q1 2026, down 99.04% YoY from $8.1 billion in Q1 2025, and down 99.43% on a QoQ basis from $13.7 billion in Q4 2025.
Gilead Sciences (GILD) Retained Earnings (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Retained Earnings data on file, last reported at $78.0 million in Q1 2026.
- Quarterly Retained Earnings fell 99.04% year-over-year to $78.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.0 million (down 99.04% YoY) and the FY2025 annual result came in at $13.7 billion, up 78.31% from the prior year.
- Retained Earnings declined to $78.0 million in Q1 2026, from $13.7 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $16.3 billion in Q4 2023 to a low of -$18.0 million in Q2 2025.
- A 5-year average of $9.0 billion and a median of $8.7 billion in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 21191.89% — and 2025, when it tumbled 119.35%.
- Tracing GILD's Retained Earnings over 5 years: stood at $15.7 billion in 2022, then climbed by 3.93% to $16.3 billion in 2023, then sank by 52.77% to $7.7 billion in 2024, then soared by 78.31% to $13.7 billion in 2025, then sank by 99.43% to $78.0 million in 2026.
- The last three Retained Earnings figures came in at $78.0 million (Q1 2026), $13.7 billion (Q4 2025), and $8.7 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.53 Bn |
| Mar 31, 2026 | 78.00 Mn |
| Dec 31, 2025 | 13.73 Bn |
| Sep 30, 2025 | 8.68 Bn |
| Jun 30, 2025 | -18.00 Mn |
| Mar 31, 2025 | 8.14 Bn |
| Dec 31, 2024 | 7.70 Bn |
| Sep 30, 2024 | 73.00 Mn |
| Jun 30, 2024 | 93.00 Mn |
| Mar 31, 2024 | 10.66 Bn |
| Dec 31, 2023 | 16.30 Bn |
| Sep 30, 2023 | 16.00 Bn |
| Jun 30, 2023 | 15.14 Bn |
| Mar 31, 2023 | 5.79 Bn |
| Dec 31, 2022 | 15.69 Bn |
| Sep 30, 2022 | 15.76 Bn |
| Jun 30, 2022 | 5.03 Bn |
| Mar 31, 2022 | 14.99 Bn |
| Dec 31, 2021 | 83.00 Mn |
| Sep 30, 2021 | 74.00 Mn |